Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
-
Published:2023-03
Issue:3
Volume:24
Page:228-238
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Author:
Choueiri Toni KORCID, Eto Masatoshi, Motzer Robert, De Giorgi Ugo, Buchler Tomas, Basappa Naveen S, Méndez-Vidal María José, Tjulandin Sergei, Hoon Park Se, Melichar Bohuslav, Hutson Thomas, Alemany Carlos, McGregor Bradley, Powles Thomas, Grünwald Viktor, Alekseev Boris, Rha Sun Young, Kopyltsov Evgeny, Kapoor Anil, Alonso Gordoa Teresa, Goh Jeffrey C, Staehler Michael, Merchan Jaime R, Xie Ran, Perini Rodolfo F, Mody Kalgi, McKenzie Jodi, Porta Camillo G
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|